Shionogi sees COVID pill reaping $2 billion in annual sales upon U.S. approval
Japan’s Shionogi & Co. believes its COVID-19 capsule will simply garner $2 billion in annual gross sales if it secures ...
Japan’s Shionogi & Co. believes its COVID-19 capsule will simply garner $2 billion in annual gross sales if it secures ...
Shionogi & Co.’s experimental COVID-19 therapy Xocova gained emergency approval in Japan, turning into the third oral therapy accessible within ...
Osaka – Japanese pharmaceutical agency Shionogi & Co. stated Wednesday its oral COVID-19 drug presently beneath improvement has been confirmed ...
An experimental remedy from Shionogi & Co. Ltd has proven speedy clearance of the virus that causes COVID-19, in accordance ...
Copyright © 2022 Asia Today.